Longevity & AgingParkinson's Cell Therapy Restores 2 Hours of Daily Function in Early Trial
A small but promising clinical trial is testing a personalized cell therapy for Parkinson's disease. The treatment uses a patient's own skin cells, reprogrammed into dopamine-producing brain cells and injected into a key motor region. In the first eight patients treated, motor function improved significantly and patients gained roughly two extra hours per day of normal movement. Quality of life scores improved by up to 51 percent. Because the cells come from the patient themselves, no immune-suppressing drugs are needed long-term. The company behind it, Aspen Neuroscience, plans to meet with the FDA and launch a larger Phase 3 trial later in 2026. While results are early and come from a small group, the data suggest this approach could meaningfully slow or partially reverse Parkinson's motor decline.
